These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22718493)

  • 1. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.
    Charbonneau B; Maurer MJ; Fredericksen ZS; Zent CS; Link BK; Novak AJ; Ansell SM; Weiner GJ; Wang AH; Witzig TE; Dogan A; Slager SL; Habermann TM; Cerhan JR
    Am J Hematol; 2012 Sep; 87(9):880-5. PubMed ID: 22718493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
    J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.
    Nowakowski GS; Maurer MJ; Habermann TM; Ansell SM; Macon WR; Ristow KM; Allmer C; Slager SL; Witzig TE; Cerhan JR
    J Clin Oncol; 2010 Jan; 28(3):412-7. PubMed ID: 20008638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
    Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
    Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
    Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
    Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
    [No Abstract]   [Full Text] [Related]  

  • 6. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.
    Keegan TH; Moy LM; Foran JM; Alizadeh AA; Chang ET; Shema SJ; Schupp CW; Clarke CA; Glaser SL
    Leuk Lymphoma; 2013 Apr; 54(4):743-51. PubMed ID: 22957852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
    Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
    Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.
    Hu W; Bassig BA; Xu J; Zheng T; Zhang Y; Berndt SI; Holford TR; Hosgood HD; Leaderer B; Yeager M; Menashe I; Boyle P; Zou K; Zhu Y; Chanock S; Lan Q; Rothman N
    Environ Mol Mutagen; 2013 Jan; 54(1):72-7. PubMed ID: 23055202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.
    Habermann TM; Wang SS; Maurer MJ; Morton LM; Lynch CF; Ansell SM; Hartge P; Severson RK; Rothman N; Davis S; Geyer SM; Cozen W; Chanock SJ; Cerhan JR
    Blood; 2008 Oct; 112(7):2694-702. PubMed ID: 18633131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
    Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
    Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma.
    Nielsen KR; Steffensen R; Haunstrup TM; Bødker JS; Dybkær K; Baech J; Bøgsted M; Johnsen HE
    Leuk Lymphoma; 2015; 56(12):3257-66. PubMed ID: 26044172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.
    Tomita N; Takasaki H; Fujisawa S; Miyashita K; Ogusa E; Kishimoto K; Matsuura S; Sakai R; Koharazawa H; Yamamoto W; Fujimaki K; Fujita H; Ishii Y; Taguchi J; Kuwabara H; Motomura S; Ishigatsubo Y
    J Clin Exp Hematop; 2013; 53(2):121-5. PubMed ID: 23995108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.
    Maurer MJ; Micallef IN; Cerhan JR; Katzmann JA; Link BK; Colgan JP; Habermann TM; Inwards DJ; Markovic SN; Ansell SM; Porrata LF; Johnston PB; Nowakowski GS; Thompson CA; Gupta M; Syrbu SI; Kurtin PJ; Macon WR; Nikcevich DA; Witzig TE
    J Clin Oncol; 2011 Apr; 29(12):1620-6. PubMed ID: 21383282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
    Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
    Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes.
    Cerhan JR; Novak AJ; Fredericksen ZS; Wang AH; Liebow M; Call TG; Dogan A; Witzig TE; Ansell SM; Habermann TM; Kay NE; Slager SL
    Br J Haematol; 2009 Jun; 145(5):614-23. PubMed ID: 19344414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.